162 related articles for article (PubMed ID: 11281398)
1. Severe cutaneous ulceration following treatment with thalidomide for GVHD.
Schlossberg H; Klumpp T; Sabol P; Herman J; Mangan K
Bone Marrow Transplant; 2001 Jan; 27(2):229-30. PubMed ID: 11281398
[TBL] [Abstract][Full Text] [Related]
2. Neuropathic dermatomes and cutaneous ulceration in patients with chronic GVHD.
Kamble RT; Scholoff A; Obi AG; Heslop HE; Brenner MK; Carrum G
Bone Marrow Transplant; 2014 Jul; 49(7):986-7. PubMed ID: 24777189
[No Abstract] [Full Text] [Related]
3. Thalidomide for the treatment of chronic graft-versus-host disease.
Vogelsang GB; Farmer ER; Hess AD; Altamonte V; Beschorner WE; Jabs DA; Corio RL; Levin LS; Colvin OM; Wingard JR
N Engl J Med; 1992 Apr; 326(16):1055-8. PubMed ID: 1549151
[TBL] [Abstract][Full Text] [Related]
4. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia.
Mehta J; Powles R; Singhal S; Iveson T; Treleaven J; Catovsky D
Bone Marrow Transplant; 1996 Mar; 17(3):371-5. PubMed ID: 8704689
[TBL] [Abstract][Full Text] [Related]
5. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children.
Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasciulli A; Vassallo E; Miniero R; Uderzo C
Bone Marrow Transplant; 1998 Mar; 21(6):577-81. PubMed ID: 9543061
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous infection with Mycobacterium fortuitum after allogeneic bone marrow transplantation.
Okano A; Shimazaki C; Ochiai N; Hatsuse M; Takahashi R; Ashihara E; Inaba T; Fujita N; Noda Y; Nakagawa M
Bone Marrow Transplant; 2001 Oct; 28(7):709-11. PubMed ID: 11704796
[TBL] [Abstract][Full Text] [Related]
7. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.
Chao NJ; Parker PM; Niland JC; Wong RM; Dagis A; Long GD; Nademanee AP; Negrin RS; Snyder DS; Hu WW; Gould KA; Tierney DK; Zwingenberger K; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1996 May; 2(2):86-92. PubMed ID: 9118303
[TBL] [Abstract][Full Text] [Related]
8. The use of thalidomide in chronic refractory graft versus host disease.
van de Poel MH; Pasman PC; Schouten HC
Neth J Med; 2001 Aug; 59(2):45-9. PubMed ID: 11476911
[TBL] [Abstract][Full Text] [Related]
9. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation.
Cole CH; Rogers PC; Pritchard S; Phillips G; Chan KW
Bone Marrow Transplant; 1994 Dec; 14(6):937-42. PubMed ID: 7711671
[TBL] [Abstract][Full Text] [Related]
11. Conjunctival Lesion in a Patient With Ocular Graft-vs-Host Disease.
Paley GL; Farooq AV; Lubniewski AJ
JAMA Ophthalmol; 2017 Aug; 135(8):883-884. PubMed ID: 28494062
[No Abstract] [Full Text] [Related]
12. Pemphigoid-like ocular lesions in patients with graft-versus-host disease following allogeneic bone marrow transplantation.
Karwacka E; Ołdakowska-Jedynak U; Brydak-Godowska J; Paczek L; Kecik D
Transplant Proc; 2006; 38(1):292-4. PubMed ID: 16504728
[TBL] [Abstract][Full Text] [Related]
13. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia.
Rondón G; Giralt S; Huh Y; Khouri I; Andersson B; Andreeff M; Champlin R
Bone Marrow Transplant; 1996 Sep; 18(3):669-72. PubMed ID: 8879640
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide responsive chronic pulmonary GVHD.
Forsyth CJ; Cremer PD; Torzillo P; Iland HJ; Young GA
Bone Marrow Transplant; 1996 Feb; 17(2):291-3. PubMed ID: 8640183
[TBL] [Abstract][Full Text] [Related]
15. Sclerodermatous chronic graft-versus-host disease--a report of four pediatric cases.
Tolland JP; Devereux C; Jones FC; Bingham EA
Pediatr Dermatol; 2008; 25(2):240-4. PubMed ID: 18429789
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide back in good graces--seems to help GVHD patients.
Oncology (Williston Park); 1988 Sep; 2(9):29. PubMed ID: 3275064
[No Abstract] [Full Text] [Related]
17. Thalidomide in the treatment of graft-versus-host disease.
Heney D; Bailey CC; Lewis IJ
Biomed Pharmacother; 1990; 44(4):199-204. PubMed ID: 2204450
[TBL] [Abstract][Full Text] [Related]
18. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
Richardson SE; Khan I; Rawstron A; Sudak J; Edwards N; Verfuerth S; Fielding AK; Goldstone A; Kottaridis P; Morris E; Benjamin R; Peggs KS; Thomson KJ; Vandenberghe E; Mackinnon S; Chakraverty R
Br J Haematol; 2013 Mar; 160(5):640-8. PubMed ID: 23293871
[TBL] [Abstract][Full Text] [Related]
19. Response to thalidomide therapy in refractory chronic graft-versus-host disease.
Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NK; Wagner J; Enright H
Bone Marrow Transplant; 2000 Oct; 26(8):865-9. PubMed ID: 11081386
[TBL] [Abstract][Full Text] [Related]
20. Extensive chronic graft-versus-host disease of skin successfully treated with thalidomide.
Nair V; Sharma A; Ghosh I; Arora S; Sahai K; Dutta V
J Assoc Physicians India; 2005 Nov; 53():988-90. PubMed ID: 16515241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
